Irritable Bowel Syndrome. Irritable bowel syndrome
Conditions
Interventions
Intervention 1: Intervention group: 500 mg mesalazine tablets 2 times a day for 8 weeks and patients 'clinical manifestations will be evaluated by a physician. Intervention 2: Control group: received
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with IBS-D according to ROME IV criteria (Loose and watery stool at at least 25% and hardy stool less than 25% of bowel movement) Age over 18 years Predominant symptom of diarrhea Calprotectin levels above 50 feces Normal colonoscopy during the last 5 years
Exclusion criteria
Exclusion criteria: Pregnancy and lactation and those who plan to become pregnant History of major abdominal surgery other than appendectomy and cholecystectomy A history of allergic disease such as asthma in yourself or a first-degree relative Celiac disease History of known psychological disease Consumption of anti-inflammatory drugs (corticosteroids, NSAIDs), mast cell stabilizers and antibiotics in the last 3 months History of inflammatory bowel disease or ulcerative colitisSensitivity to sulfur-containing compounds such as mesalazine Consumption of lactulose and recent probiotics Evidence of organic disease in colonoscopy Normal stool calprotectin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abdominal pain. Timepoint: Before and 8 weeks after the intervention. Method of measurement: visual analog scale (0=no pain; 10= worst pain).;Bloating. Timepoint: Before and 8 weeks after the intervention. Method of measurement: Based on a questionnaire.;Diarrhea. Timepoint: Before and 8 weeks after the intervention. Method of measurement: Based on the prepared questionnaire, the number of diarrhea per day will be measured.;Consumption of mesalazine. Timepoint: Before and 8 weeks after the intervention. Method of measurement: Based on a questionnaire.;Fecal calprotectin levels. Timepoint: Before and 8 weeks after the intervention. Method of measurement: ELISA method with laboratory kit (calprest). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Mehdi Rasoolimanesh
Tabriz University of Medical Sciences
Outcome results
None listed